Aider is a “pair-programming” tool that can use various providers as the AI back end, including a locally running instance of ...

Even as they build out agentic tools themselves, leaders from the two companies say the capabilities aren’t quite there yet.

Doher Drizzle Pablo was drowning in travel receipts. After her company transferred her to Sweden from the Philippines last year, she’d started visiting clients in at least two countries a month, and ...

Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...

Multiple analysts have issued price targets for $REPL recently. We have seen 4 analysts offer price targets for $REPL in the last 6 months, with a median target of ...

While letting AI take the wheel and write the code for your website may seem like a good idea, it’s not without its limitations. MIT Technology Review Explains: Let our writers untangle the complex, ...